Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non–Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non–Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started